Pacira Pharmaceuticals, Inc. (PCRX) is a publicly traded company in the Unknown sector. Across all available filings, 54 corporate insiders have executed 1022 transactions totaling $459.4M, demonstrating a bearish sentiment with -$412.8M in net insider flow. The most recent transaction on Feb 2, 2026 involved a sale of 13,137 shares valued at $269.7K.
No significant insider buying has been recorded for PCRX in the recent period.
No significant insider selling has been recorded for PCRX in the recent period.
Based on recent SEC filings, insider sentiment for PCRX is bearish with an Insider Alignment Score of 5/100 and a net flow of -$412.8M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Pacira Pharmaceuticals, Inc. (PCRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 54 insiders are actively trading PCRX stock, having executed 1022 transactions in the past 90 days. The most active insider is Andreas Wicki (Executive), who has made 82 transactions totaling $149.2M.
Get notified when executives and directors at PCRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Williams Kristen | Chief Administrative Officer | Sale | 13,137 | $20.53 | $269.7K | |
| Feb 2, 2026 | Riker Lauren | Senior Vice President, Finance | Sale | 4,000 | $20.81 | $83.2K | |
| Jan 30, 2026 | D. Lee Frank | Executive | Payment | 41,488 | $20.54 | $852.2K | Large |
| Jan 30, 2026 | Teehan Brendan | Chief Commercial Officer | Payment | 5,182 | $20.54 | $106.4K | |
| Jan 30, 2026 | Slonin Jonathan | Chief Medical Officer | Payment | 6,168 | $20.54 | $126.7K | |
| Jan 30, 2026 | Williams Kristen | Chief Administrative Officer | Payment | 17,134 | $20.54 | $351.9K | |
| Jan 30, 2026 | Riker Lauren | Senior Vice President, Finance | Payment | 2,751 | $20.54 | $56.5K | |
| Jan 5, 2026 | Riker Lauren | Senior Vice President, Finance | Sale | 1,416 | $24.24 | $34.3K | |
| Jan 2, 2026 | D. Lee Frank | Executive | Payment | 9,272 | $24.46 | $226.8K | |
| Jan 2, 2026 | Riker Lauren | Senior Vice President, Finance | Payment | 159 | $24.46 | $3.9K | |
| Jan 2, 2026 | Slonin Jonathan | Chief Medical Officer | Payment | 381 | $24.46 | $9.3K | |
| Dec 31, 2025 | Teehan Brendan | Chief Commercial Officer | Award | 402.27 | $10.76 | $4.3K | |
| Dec 10, 2025 | Cross Shawn | Executive | Sale | 9,104 | $25.14 | $228.9K | |
| Dec 10, 2025 | Cross Shawn | Executive | Option Exercise | 9,104 | $16.45 | $149.8K | |
| Dec 9, 2025 | Cross Shawn | Executive | Sale | 15,896 | $25.03 | $397.9K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 539 | $436.1M | 88.5% |
Exercise(M) | 228 | $28.8M | 5.8% |
Purchase(P) | 37 | $23.3M | 4.7% |
Payment(F) | 18 | $2.3M | 0.5% |
Exercise (Options)(X) | 19 | $2.1M | 0.4% |
Award(A) | 155 | $18.9K | 0.0% |
Gift(G) | 6 | $0 | 0.0% |
Other(J) | 14 | $0 | 0.0% |
Conversion(C) | 6 | $0 | 0.0% |
Insider selling pressure at Pacira Pharmaceuticals, Inc. has increased, with 54 insiders executing 1022 transactions across all time. Total sales of $436.1M significantly outpace purchases of $23.3M, resulting in a net outflow of $412.8M. This selling activity appears largely discretionary, which may warrant closer attention from investors.